Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer.
An EORTC type I clinical trial of 2-bromo-alpha ergocryptine was performed in patients with prostatic carcinoma in clinical stages III and IV. Evaluating rules of response to the therapy were based on objective criteria. The maximum period of followup was 16 weeks. No objective remissions were observed in 24 patients, and in 13 of these patients, evidence of progression of the disease was apparent during the first 8 weeks of drug administration.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004487:Edema / Q000139:chemically induced; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D011388:Prolactin / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin